PDF(Pubmed)
Abstract：
Teriparatide, an osteoanabolic agent, is a biosynthetic analogue of the 1-34 amino acids of human parathyroid hormone (PTH) used for the treatment of osteoporosis. It is typically well-tolerated; common side effects include headaches, arthralgias, nausea, and dizziness. In this report, we present a case of gynecomastia occurring shortly after initiating teriparatide therapy, associated with nipple sensitivity and breast tenderness. Secondary workup for various causes of gynecomastia was unremarkable. Finally, a decision was made to discontinue teriparatide due to the patient\'s concerns. The nipple sensitivity started improving shortly afterward, with complete resolution of gynecomastia 4 months later. Although this unusual side effect has been reported as a possibility in postmarketing studies, a chronological report on the occurrence of teriparatide-induced gynecomastia and its complete resolution after discontinuing teriparatide has not yet been published in the literature.
摘要：
特立帕肽,一种骨合成代谢剂，是用于治疗骨质疏松症的人甲状旁腺激素（PTH）的1-34个氨基酸的生物合成类似物。它通常具有良好的耐受性；常见的副作用包括头痛，关节痛,恶心,和头晕。在这份报告中,我们介绍了一例开始特立帕肽治疗后不久发生的男性乳房发育症，与乳头敏感和乳房压痛有关。各种原因的男性乳房发育症的二次检查并不明显。最后,由于患者的担忧，决定停用特立帕肽。乳头敏感性很快开始改善，4个月后妇科乳房发育完全消退。虽然这种不寻常的副作用在上市后研究中被报道为一种可能性，关于特立帕肽诱导的男性乳房发育症的发生及其在停用特立帕肽后完全缓解的时间顺序报告尚未在文献中发表。
